Skip to main content
Log in

Poststroke Dementia in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Risk of dementia increases after stroke, and poststroke dementia (PSD) is an important cause of disability in the elderly. The prevalence rates of PSD vary from 12.2% to 31.8% within 3 months to 1 year after stroke, depending on patient populations and the diagnostic criteria used in the numerous studies. Incidence rates of PSD increase with time after the stroke.

Although vascular lesions and white matter changes can explain the cognitive disorders seen in stroke patients, an underlying neurodegenerative disorder may contribute to the development of PSD. Cognitive decline may pre-date the stroke and follow a progressive course after the stroke. The vascular and degenerative processes involved share common environmental and genetic risk factors.

This review explains the mechanisms of dementia in stroke patients and identifies predictive factors for PSD. The following points are successively considered: (i) demographic characteristics of the patients, including age and level of education; (ii) prestroke cognitive decline; (iii) vascular risk factors, including diabetes mellitus and prior strokes; (iv) stroke characteristics, including severity and location of the vascular lesion; (v) co-morbid disorders; and (vi) abnormalities on brain imaging, including location, size and number of vascular lesions, white matter changes and cerebral atrophy. Older age, prestroke cognitive decline, stroke recurrence, hypoxic-ischaemic disorders, left-side infarcts, strategic infarcts and white matter lesions appear to be the main predictive factors of PSD.

Prevention of stroke should reduce the morbidity and mortality associated with PSD. In addition, management of PSD with secondary prevention treatments could reduce occurrence of further strokes. Cholinesterase inhibitors may be beneficial not only in Alzheimer’s disease associated with cerebrovascular lesions, but also for the treatment of cholinergic dysfunction arising from pure vascular dementia. Better knowledge of the risk factors for PSD, including environmental and genetic factors, should increase the effectiveness of preventive strategies in patients with this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O’Brien J, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003; 2: 89–98

    Article  PubMed  Google Scholar 

  2. Prencipe M, Ferretti C, Casini AR, et al. Stroke, disability, and dementia: results of a population survey. Stroke 1997; 28(3): 531–6

    Article  PubMed  CAS  Google Scholar 

  3. van Kooten F, Bots ML, Breteler MM, et al. The Dutch Vascular Factors in Dementia Study: rationale and design. J Neurol 1998; 245(1): 32–9

    Article  PubMed  Google Scholar 

  4. Brayne C, Gill C, Huppert FA, et al. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998; 9(3): 175–80

    Article  PubMed  CAS  Google Scholar 

  5. Zhu L, Fratiglioni L, Guo Z, et al. Association of stroke with dementia, cognitive impairment, and functional disability in the very old: a population-based study. Stroke 1998; 29(10): 2094–9

    Article  PubMed  CAS  Google Scholar 

  6. Andersen G, Vestergaard K, Riis JO, et al. Intellectual impairment in the first year following stroke compared to an age-matched population sample. Cerebrovasc Dis 1996; 6: 363–9

    Article  Google Scholar 

  7. Tatemichi TK, Desmond DW, Mayeux R, et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992; 42(6): 1185–93

    Article  PubMed  CAS  Google Scholar 

  8. Censori B, Manara O, Agostinis C, et al. Dementia after first stroke. Stroke 1996; 27: 1205–10

    Article  PubMed  CAS  Google Scholar 

  9. Inzitari D, Di Carlo A, Pracucci G, et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 1998; 29(10): 2087–93

    Article  PubMed  CAS  Google Scholar 

  10. Pohjasvaara T, Erkinjuntti T, Ylikoski R, et al. Clinical determinants of post-stroke dementia. Stroke 1998; 29(1): 75–81

    Article  PubMed  CAS  Google Scholar 

  11. Desmond DW, Moroney JT, Paik MC, et al. Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000; 54(5): 1124–31

    Article  PubMed  CAS  Google Scholar 

  12. Rasquin SM, Lodder J, Ponds RW, et al. Cognitive functioning after stroke: a one-year follow-up study. Dement Geriatr Cogn Disord 2004; 18(2): 138–44

    Article  PubMed  Google Scholar 

  13. Linden T, Skoog I, Fagerberg B, et al. Cognitive impairment and dementia 20 months after stroke. Neuroepidemiology 2004; 23(1–2): 45–52

    PubMed  Google Scholar 

  14. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd ed. Washington, DC: American Psychiatric Association, 1980

    Google Scholar 

  15. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Orgnization, 1993

    Google Scholar 

  16. Pohjasvaara T, Erkinjuntti T, Vataja R, et al. Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinski Stroke Aging Memory Study (SAM) cohort. Stroke 1997; 28(4): 785–92

    Article  PubMed  CAS  Google Scholar 

  17. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993; 33(6): 568–75

    Article  PubMed  CAS  Google Scholar 

  18. Tatemichi TK, Paik M, Bagiella E, et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994; 44(10): 1885–91

    Article  PubMed  CAS  Google Scholar 

  19. Desmond DW, Bagiella E, Moroney JT, et al. The effect of patient attrition on estimates of the frequency of dementia following stroke. Arch Neurol 1998; 55(3): 390–4

    Article  PubMed  CAS  Google Scholar 

  20. Hénon H, Pasquier F, Durieu I, et al. Preexisting dementia in stroke patients: baseline frequency, associated factors, and outcome. Stroke 1997; 28(12): 2429–36

    Article  PubMed  Google Scholar 

  21. Pohjasvaara T, Mantyla R, Aronen HJ, et al. Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort. J Neurol Neurosurg Psychiatry 1999; 67(6): 742–8

    Article  PubMed  CAS  Google Scholar 

  22. Barba R, Castro MD, del Mar Morin M, et al. Prestroke dementia. Cerebrovasc Dis 2001; 11(3): 216–24

    Article  PubMed  CAS  Google Scholar 

  23. Klimkowicz A, Dziedzic T, Slowik A, et al. Incidence of preand poststroke dementia: Cracow stroke registry. Dement Geriatr Cogn Disord 2002; 14(3): 137–40

    Article  PubMed  Google Scholar 

  24. Tang WK, Chan SS, Chiu HF, et al. Frequency and determinants of prestroke dementia in a Chinese cohort. J Neurol 2004; 251(5): 604–8

    Article  PubMed  Google Scholar 

  25. Aronovich BD, Treves TA, Bornstein NM, et al. Dementia after first stroke: 3-years survival analysis. Cerebrovasc Dis 1992; 2: 216

    Article  Google Scholar 

  26. Hénon H, Durieu I, Guerouaou D, et al. Postroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 2001; 57(7): 1216–22

    Article  PubMed  Google Scholar 

  27. Altieri M, Di Piero V, Pasquini M, et al. Delayed poststroke dementia: a 4-year follow-up study. Neurology 2004; 62(12): 2193–7

    Article  PubMed  CAS  Google Scholar 

  28. Bornstein NM, Gur AY, Treves TA, et al. Do silent brain infarctions predict the development of dementia after first ischemic stroke? Stroke 1996; 27(5): 904–5

    Article  PubMed  CAS  Google Scholar 

  29. Kokmen E, Whisnant JP, O’Fallon WM, et al. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960–1984). Neurology 1996; 46(1): 154–9

    Article  PubMed  CAS  Google Scholar 

  30. Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke 2004; 35(6): 1264–8

    Article  PubMed  Google Scholar 

  31. Honig LS, Tang M-X, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003; 60(12): 1707–12

    Article  PubMed  Google Scholar 

  32. Gorelick PB. Status of risk factors for dementia associated with stroke. Stroke 1997; 28(2): 459–63

    Article  PubMed  CAS  Google Scholar 

  33. Rasquin SM, Verhey FR, Lousberg R, et al. Vascular cognitive disorders: memory, mental speed and cognitive flexibility after stroke. J Neurol Sci 2002; 203–204: 115–9

    Article  PubMed  Google Scholar 

  34. Ballard C, Rowan E, Stephens S, et al. Prospective follow-up study between 3 and 15 months after stroke: improvements and decline in cognitive function among dementia-free stroke survivors >75 years of age. Stroke 2003; 34(10): 2440–4

    Article  PubMed  Google Scholar 

  35. Zhu L, Fratiglioni L, Guo Z, et al. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old: findings from a population-based longitudinal study. Stroke 2000; 31(1): 53–60

    Article  PubMed  CAS  Google Scholar 

  36. Leys D, Erkinjuntti T, Desmond DW, et al. Vascular dementia: the role of cerebral infarcts. Alzheimer Dis Assoc Disord 1999; 13Suppl. 3: S38–48

    PubMed  Google Scholar 

  37. Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol 1997; 244(3): 135–42

    Article  PubMed  CAS  Google Scholar 

  38. Burton EJ, Kenny RA, O’Brien J, et al. White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. Stroke 2004; 35(6): 1270–5

    Article  PubMed  Google Scholar 

  39. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 1997; 277(10): 813–7

    Article  PubMed  CAS  Google Scholar 

  40. Nagy Z, Esiri MM, Jobst KA, et al. The effects of additional pathology on the cognitive deficit in Alzheimer’s disease. J Neuropathol Exp Neurol 1997; 56(2): 165–70

    Article  PubMed  CAS  Google Scholar 

  41. Tatemichi TK. How acute brain failure becomes chronic: a view of the mechanisms of dementia related to stroke. Neurology 1990; 40(11): 1652–9

    Article  PubMed  CAS  Google Scholar 

  42. Hénon H, Pasquier F, Durieu I, et al. Medial temporal lobe atrophy in stroke patients: relationship with pre-existing dementia. J Neurol Neurosurg Psychiatry 1998; 65(5): 641–7

    Article  PubMed  Google Scholar 

  43. Hénon H, Lebert F, Durieu I, et al. Confusional state in stroke: relation to preexisting dementia, patient characteristics, and outcome. Stroke 1999; 30(4): 773–9

    Article  PubMed  Google Scholar 

  44. Tang WK, Chan SS, Chiu HF, et al. Impact of applying NINDSAIREN criteria of probable vascular dementia to clinical and radiological characteristics of a stroke cohort with dementia. Cerebrovasc Dis 2004; 18(2): 98–103

    Article  PubMed  Google Scholar 

  45. Ashford JW. APOE genotype effects on Alzheimer’s disease onset and epidemiology. J Mol Neurosci 2004; 23(3): 157–65

    Article  PubMed  CAS  Google Scholar 

  46. Prince M, Lovestone S, Cervilla J, et al. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology 2000; 54(2): 397–402

    Article  PubMed  CAS  Google Scholar 

  47. Slooter AJ, Cruts M, Ott A, et al. The effect of APOE on dementia is not through atherosclerosis: the Rotterdam Study. Neurology 1999; 53(7): 1593–5

    Article  PubMed  CAS  Google Scholar 

  48. Premkumar DR, Cohen DL, Hedera P, et al. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol 1996; 148(6): 2083–95

    PubMed  CAS  Google Scholar 

  49. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 1999; 53(6): 1308–11

    Article  PubMed  CAS  Google Scholar 

  50. McCarron MO, Muir KW, Weir CJ, et al. The apolipoprotein E epsilon4 allele and outcome in cerebrovascular disease. Stroke 1998; 29(9): 1882–7

    Article  CAS  Google Scholar 

  51. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141(2): 137–47

    PubMed  Google Scholar 

  52. Slooter AJ, Cruts M, Hofman A, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology 2004; 62(7): 1196–8

    Article  PubMed  CAS  Google Scholar 

  53. Lin HF, Lai CL, Tai C, et al. Apolipoprotein E polymorphism in ischemic cerebrovascular diseases and vascular dementia patients in Taiwan. Neuroepidemiology 2004; 23(3): 129–34

    Article  PubMed  Google Scholar 

  54. Basun H, Corder EH, Guo Z, et al. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke 1996; 27(8): 1310–5

    Article  PubMed  CAS  Google Scholar 

  55. Bleumink GS, van Duijn CM, Kingma JH, et al. Apolipoprotein E epsilon4 allele, is associated with left ventricular systolic dysfunction. Am Heart J 2004; 147(4): 685–9

    Article  PubMed  CAS  Google Scholar 

  56. Frisoni GB, Calabresi L, Geroldi C, et al. Apolipoprotein E 84 allele in Alzheimer’s disease and vascular dementia. Dementia 1994; 5(5): 240–2

    PubMed  CAS  Google Scholar 

  57. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham Study. Neurology 1996; 46(3): 673–7

    Article  PubMed  CAS  Google Scholar 

  58. Treves TA, Bornstein NM, Chapman J, et al. APOE-epsilon 4 in patients with Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1996; 10(4): 189–91

    Article  PubMed  CAS  Google Scholar 

  59. Isoe K, Urakami K, Sato K, et al. Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia. Acta Neurol Scand 1996; 93(2–3): 133–7

    PubMed  CAS  Google Scholar 

  60. Slooter AJC, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke: a population-based investigation. JAMA 1997; 277(10): 818–21

    Article  PubMed  CAS  Google Scholar 

  61. Marin DB, Breuer B, Marin ML, et al. The relationship between apolipoprotein E, dementia, and vascular illness. Atherosclerosis 1998; 140(1): 173–80

    Article  PubMed  CAS  Google Scholar 

  62. Yang J, Feng G, Zhang J, et al. is ApoE gene a risk factor for vascular dementia in Han Chinese. Int J Mol Med 2001; 7(2): 217–9

    PubMed  CAS  Google Scholar 

  63. Luthra K, Tripathi M, Grover R, et al. Apolipoprotein E gene polymorphism in Indian patients with Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 2004; 17(3): 132–5

    Article  PubMed  CAS  Google Scholar 

  64. Pirttila T, Lehtimaki T, Rinne J, et al. The frequency of apolipoprotein E4 allele is not increased in patients with probable vascular dementia. Acta Neurol Scand 1996; 93(5): 352–4

    Article  PubMed  CAS  Google Scholar 

  65. Traykov L, Rigaud A-S, Caputo L, et al. Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. Eur J Neurol 1999; 6(4): 415–21

    Article  PubMed  CAS  Google Scholar 

  66. Molero AE, Pino-Ramirez G, Maestre GE. Modulation by age and gender of risk for Alzheimer’s disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study. Neurosci Lett 2001; 307(1): 5–8

    Article  PubMed  CAS  Google Scholar 

  67. Frank A, Diez-Tejedor E, Bullido MJ, et al. APOE genotype in cerebrovascular disease and vascular dementia. J Neurol Sci 2002; 203–204: 173–6

    Article  PubMed  Google Scholar 

  68. Traykov L, Rigaud A-S, Baudic S, et al. Apolipoprotein E epsilon 4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease. J Neurol Sci 2002; 203–204: 177–81

    Article  PubMed  Google Scholar 

  69. Lai CL, Tai CT, Lin SR, et al. Apolipoprotein E in Taiwan Chinese patients with dementia. Dement Geriatr Cogn Disord 2003; 16(4): 208–11

    Article  PubMed  CAS  Google Scholar 

  70. Nielsen AS, Ravid R, Kamphorst W, et al. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. J Alzheimers Dis 2003; 5(2): 119–25

    PubMed  CAS  Google Scholar 

  71. Sulkava R, Kainulainen K, Verkkoniemi A, et al. APOE alleles in Alzheimer’s disease and vascular dementia in a population aged 85+. Neurobiol Aging 1996; 17(3): 373–6

    Article  PubMed  CAS  Google Scholar 

  72. Skoog I, Hesse C, Aevarsson O, et al. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998; 64(1): 37–43

    Article  PubMed  CAS  Google Scholar 

  73. Engelborghs S, Dermaut B, Goeman J, et al. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry 2003; 74(8): 1148–51

    Article  PubMed  CAS  Google Scholar 

  74. Dik MG, Deeg DJ, Bouter LM, et al. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: a population-based study. Stroke 2000; 31(10): 2431–6

    Article  PubMed  CAS  Google Scholar 

  75. Johnston JM, Nazar-Stewart V, Kelsey SF, et al. Relationships between cerebrovascular events, APOE polymorphism and Alzheimer’s disease in a community sample. Neuroepidemiology 2000; 19(6): 320–6

    Article  PubMed  CAS  Google Scholar 

  76. Kalmijn S, Feskens EJM, Launer LJ, et al. Cerebrovascular disease, the apolipoprotein 84 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996; 27(12): 2230–5

    Article  PubMed  CAS  Google Scholar 

  77. de Leeuw FE, Richard F, de Groot JC, et al. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004; 35(5): 1057–60

    Article  PubMed  CAS  Google Scholar 

  78. Tang J, Zhao J, Zhao Y, et al. Apolipoprotein E epsilon4 and the risk of unfavorable outcome after aneurysmal subarachnoid hemorrhage. Surg Neurol 2003; 60(5): 391–6

    Article  PubMed  Google Scholar 

  79. de Stefano N, Bartolozzi ML, Nacmias B, et al. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004; 61(4): 536–40

    Article  PubMed  Google Scholar 

  80. Lendon CL, Harris JM, Pritchard AL, et al. Genetic variation of the APOE promoter and outcome after head injury. Neurology 2003; 61(5): 683–5

    Article  PubMed  CAS  Google Scholar 

  81. Sundstrom A, Marklund P, Nilsson LG, et al. APOE influences on neuropsychological function after mild head injury: within-person comparisons. Neurology 2004; 62(11): 1963–6

    Article  PubMed  CAS  Google Scholar 

  82. Kalaria RN. Small vessel disease and Alzheimer’s dementia: pathological considerations. Cerebrovasc Dis 2002; 13Suppl. 2: 48–52

    Article  PubMed  CAS  Google Scholar 

  83. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986; 19(3): 253–62

    Article  PubMed  CAS  Google Scholar 

  84. Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, Part XV. Neurology 1996; 46(6): 1592–6

    Article  PubMed  CAS  Google Scholar 

  85. Tatemichi TK, Foulkes M, Mohr JP, et al. Dementia in stroke survivors in the Stroke Data Bank cohort: prevalence, incidence, risk factors, and computed tomographic findings. Stroke 1990; 21(6): 858–66

    Article  PubMed  CAS  Google Scholar 

  86. Cordoliani-Mackowiak MA, Henon H, Pruvo J-P, et al. Post-stroke dementia: influence of hippocampal atrophy. Arch Neurol 2003; 60(4): 585–90

    Article  PubMed  Google Scholar 

  87. Pohjasvaara T, Mantyla R, Salonen O, et al. MRI correlates of dementia after first clinical ischemic stroke. J Neurol Sci 2000; 181(1–2): 111–7

    Article  PubMed  CAS  Google Scholar 

  88. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack [published erratum appears in Lancet 2001; 358 (9292): 1556. Published erratum appears in Lancet 2002; 359 (9323): 2120]. Lancet 2001; 358(9287): 1033–41

    Article  Google Scholar 

  89. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163(9): 1069–75

    Article  PubMed  CAS  Google Scholar 

  90. Englund E, Brun A. White matter changes in dementia of Alzheimer’s type: biochemical and neuropathological correlates. Brain 1988; 111(6): 1425–9

    Article  PubMed  Google Scholar 

  91. Desmond DW. Vascular dementia: a construct in evolution. Cerebrovasc Brain Metab Rev 1996; 8(4): 296–325

    PubMed  CAS  Google Scholar 

  92. Gorelick PB, Brody J, Cohen D, et al. Risk factors for dementia associated with multiple cerebral infarcts: a case-control analysis in predominantly African-American hospital-based patients. Arch Neurol 1993; 50(7): 714–20

    Article  PubMed  CAS  Google Scholar 

  93. Moroney JT, Bagiella E, Desmond DW, et al. Risk factors for incident dementia after stroke: role of hypoxic and ischemic disorders. Stroke 1996; 27(8): 1283–9

    Article  PubMed  CAS  Google Scholar 

  94. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154(7): 635–41

    Article  PubMed  CAS  Google Scholar 

  95. Woo J, Lam CW, Kay R, et al. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol 1990; 47(11): 1174–7

    Article  PubMed  CAS  Google Scholar 

  96. Breteler MMB, Bots ML, Ott A, et al. Risk factors for vascular disease and dementia. Haemostasis 1998; 28(3–4): 167–73

    PubMed  CAS  Google Scholar 

  97. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002; 346(7): 476–83

    Article  PubMed  CAS  Google Scholar 

  98. McIlroy SP, Dynan KB, Lawson JT, et al. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002; 33(10): 2351–6

    Article  PubMed  CAS  Google Scholar 

  99. Maxwell CJ, Hogan DB, Ebly EM. Serum folate levels and subsequent adverse cerebrovascular outcomes in elderly persons. Dement Geriatr Cogn Disord 2002; 13(4): 225–34

    Article  PubMed  CAS  Google Scholar 

  100. Desmond DW, Moroney JT, Sano M, et al. Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke 2002; 33(9): 2254–60

    Article  PubMed  Google Scholar 

  101. Appelros P, Nydevik I, Sciger A, et al. Predictors of severe stroke: influence of preexisting dementia and cardiac disorders. Stroke 2002; 33(10): 2357–62

    Article  PubMed  Google Scholar 

  102. Hénon H, Durieu I, Lebert F, et al. Influence of prestroke dementia on early and delayed mortality in stroke patients. J Neurol 2003; 250(1): 10–6

    Article  PubMed  Google Scholar 

  103. Mok VC, Wong A, Lam WW, et al. Cognitive impairment and functional outcome after stroke associated with small vessel disease. J Neurol Neurosurg Psychiatry 2004; 75(4): 560–6

    Article  PubMed  CAS  Google Scholar 

  104. Erkinjuntti T, Bowler JV, DeCarli CS, et al. Imaging of static brain lesions in vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord 1999; 13Suppl. 3: S81–90

    PubMed  Google Scholar 

  105. Liu CK, Miller BL, Cummings JL, et al. A quantitative MRI study of vascular dementia. Neurology 1992; 42(1): 138–43

    Article  PubMed  CAS  Google Scholar 

  106. Pohjasvaara T, Mantyla R, Salonen O, et al. How complex interaction of ischemic brain infarct, white matter lesions and atrophy relate to post-stroke dementia. Arch Neurol 2000; 57: 1295–300

    Article  PubMed  CAS  Google Scholar 

  107. Fukuda H, Kobayashi S, Okada K, et al. Frontal white matter lesions and dementia in lacunar infarction. Stroke 1990; 21(8): 1143–9

    Article  PubMed  CAS  Google Scholar 

  108. Inzitari D, Di Carlo A, Mascalchi M, et al. The cardiovascular outcome of patients with motor impairment and extensive leukoaraiosis. Arch Neurol 1995; 52(7): 687–91

    Article  PubMed  CAS  Google Scholar 

  109. Leys D, Englund E, Del Ser T, et al. White matter changes in stroke patients: relationship with stroke subtype and outcome. Eur Neurol 1999; 42(2): 67–75

    Article  PubMed  CAS  Google Scholar 

  110. Breteler MM, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994; 44(7): 1246–52

    Article  PubMed  CAS  Google Scholar 

  111. Wen HM, Mok VC, Fan YH, et al. Effect of white matter changes on cognitive impairment in patients with lacunar infarcts. Stroke 2004; 35(8): 1826–30

    Article  PubMed  Google Scholar 

  112. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol 1987; 44(1): 21–3

    Article  PubMed  CAS  Google Scholar 

  113. Ishii N, Nishihara Y, Imamura T. Why do frontal lobe symptoms predominate in vascular dementia with lacunes? Neurology 1986; 36: 340–5

    Article  PubMed  CAS  Google Scholar 

  114. Bigler ED, Kerr B, Victoroff J, et al. White matter lesions, quantitative magnetic resonance imaging, and dementia. Alzheimer Dis Assoc Disord 2002; 16(3): 161–70

    Article  PubMed  Google Scholar 

  115. Capizzano AA, Acion L, Bekinschtein T, et al. White matter hyperintensities are significantly associated with cortical atrophy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004; 75(6): 822–7

    Article  PubMed  CAS  Google Scholar 

  116. Piguet O, Ridley L, Grayson DA, et al. Are MRI white matter lesions clinically significant in the ‘old-old’? Evidence from the Sydney Older Persons Study. Dement Geriatr Cogn Disord 2003; 15(3): 143–50

    Article  PubMed  Google Scholar 

  117. Tatemichi TK, Paik M, Bagiella E, et al. Dementia after stroke is a predictor of long-term survival. Stroke 1994; 25(10): 1915–9

    Article  PubMed  CAS  Google Scholar 

  118. Desmond DW, Moroney JT, Sano M, et al. Mortality in patients with dementia after ischemic stroke. Neurology 2002; 59(4): 537–43

    Article  PubMed  Google Scholar 

  119. Barba R, Morin MD, Cemillan C, et al. Previous and incident dementia as risk factors for mortality in stroke patients. Stroke 2002; 33(8): 1993–8

    Article  PubMed  Google Scholar 

  120. Moroney JT, Tseng C-L, Paik MC, et al. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J Am Geriatr Soc 1999; 47: 824–9

    PubMed  CAS  Google Scholar 

  121. Moroney JT, Bagiella E, Tatemichi TK, et al. Dementia after stroke increases the risk of long-term stroke recurrence. Neurology 1997; 48(5): 1317–25

    Article  PubMed  CAS  Google Scholar 

  122. Henon H, Vroylandt P, Durieu I, et al. Leukoaraiosis more than dementia is a predictor of stroke recurrence. Stroke 2003; 34(12): 2935–40

    Article  PubMed  CAS  Google Scholar 

  123. Forette F, Seux M-L, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352(9137): 1347–51

    Article  PubMed  CAS  Google Scholar 

  124. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc 1996; 44(4): 411–5

    PubMed  CAS  Google Scholar 

  125. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21(5): 875–86

    Article  PubMed  CAS  Google Scholar 

  126. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24): 3255–64

    Google Scholar 

  127. Kimura S, Saito H, Minami M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153(1–3): 167–78

    Article  PubMed  CAS  Google Scholar 

  128. Gottfries C-G, Blennow K, Karlsson I, et al. The neurochemistry of vascular dementia. Dementia 1994; 5(3–4): 163–7

    PubMed  CAS  Google Scholar 

  129. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34(10): 2323–30

    Article  PubMed  CAS  Google Scholar 

  130. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61(4): 479–86

    Article  PubMed  CAS  Google Scholar 

  131. Kurz AF, Erkinjuntti T, Small GW, et al. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer’s disease with cerebrovascular disease. Eur J Neurol 2003; 10(6): 633–40

    Article  PubMed  CAS  Google Scholar 

  132. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; (1): CD004395

    Google Scholar 

  133. Bullock R. Cholinesterase inhibitors and vascular dementia: another string to their bow? CNS Drugs 2004; 18(2): 79–92

    Article  PubMed  CAS  Google Scholar 

  134. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359(9314): 1283–90

    Article  PubMed  Google Scholar 

  135. Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia [published erratum appears in Clin Ther 2003; 25 (8): 2336]. Clin Ther 2003; 25(6): 1765–82

    Article  PubMed  CAS  Google Scholar 

  136. Rockwood K, Wentzel C, Hachinski V, et al. Prevalence and outcomes of vascular cognitive impairment. Neurology 2000; 54(2): 447–51

    Article  PubMed  CAS  Google Scholar 

  137. Ballard C, Stephens S, Kenny RA, et al. Profile of neuropsychological deficits in older stroke survivors without dementia. Dement Geriatr Cogn Disord 2003; 16(1): 52–6

    Article  PubMed  Google Scholar 

  138. Stephens S, Kenny RA, Allan L, et al. Neuropsychological characteristics of mild cognitive impairment and dementia after stroke. Int J Geriatr Psychiatry 2004; 19(11): 1053–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by EA 1691, from the Ministère de l’Education nationale, de l’Enseignement supérieur et de la Recherche.

The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marie-Anne Mackowiak-Cordoliani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mackowiak-Cordoliani, MA., Bombois, S., Memin, A. et al. Poststroke Dementia in the Elderly. Drugs Aging 22, 483–493 (2005). https://doi.org/10.2165/00002512-200522060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522060-00003

Keywords

Navigation